Supreme Court Hears Challenge to Tennessees SB 1, Justices Divided Over Whether Law Classifies by Birth Sex

Solicitor General Prelogar told the Supreme Court on argument day that Tennessees SB 1 draws a sex-based line on its face by banning medications "when and only when it's inconsistent with the patient's birth sex," and she urged the justices to treat the statute as a facial sex-based classification deserving heightened scrutiny or, at minimum, to remand for that analysis. "SB 1 categorically bans treatment when and only when it's inconsistent with the patient's birth sex," she said, arguing that the statute leaves no individualized exception even where doctors and parents have concluded treatment is medically necessary.

The Court's questioning, spanning discussions of medical evidence, doctrine, and democratic decisionmaking, focused on two central questions: whether SB 1 actually classifies on the basis of birth sex (or instead draws lines on the basis of age and medical purpose), and if it does, what level of judicial review and remedial relief are appropriate.

Justices pressed both sides about evolving international guidance and the evidence base. Justice Alito cited recent European reports and asked whether the Solicitor General would stand by her petitions claim that "overwhelming evidence" supports benefits from puberty blockers and hormones; Prelogar replied that some European bodies have restricted new prescriptions but have not enacted a categorical ban and that many major U.S. medical organizations recognize that the treatments can be "medically necessary for some adolescents."

Several justices raised the stakes for adolescents. Justice Sotomayor asked whether the evidence is clear that the treatments can materially reduce depression, anxiety, and suicidality for some youths; Prelogar said the record and clinical practice indicate the care can be essential and that the district court found many of Tennessee's asserted risks unsubstantiated. She warned that a categorical ban forces all minors to undergo puberty consistent with their birth sex regardless of individualized medical analysis.

Other justices, including Justice Kagan, pressed whether the statute is better understood as discrimination against transgender youth rather than simply a sex-based rule, and how doctrinal tools from cases such as Bostock, Arlington Heights, and Loving should guide the analysis. The Solicitor General argued the two lines of analysis are compatible: SB 1s text imposes restrictions "inconsistent with sex," which on its face creates sex-based classifications that also disfavor transgender-identifying minors.

Tennessees counsel, Mr. Rice, defended SB 1 as a purpose-based statute that distinguishes medical uses of drugs and is intended to protect minors amid medical uncertainty. "The law imposes an across-the-board rule that allows the use of drugs and surgeries for some medical purposes, but not for others," Rice said, arguing that the equal protection clause does not require courts to "blind themselves to medical reality." He emphasized legislative prerogative and the role of politically accountable lawmakers in addressing evolving science.

Justices repeatedly asked whether the Court should defer to legislative judgments about medical risk and whether a ruling for the challengers would have spillover effects for other contested questions such as sports eligibility. Counsel for the challengers said the Court could decide the threshold classification question narrowly without foreclosing tailored state regulations that survive heightened scrutiny; counsel for the state warned the Court against constitutionalizing what they described as an unsettled medical policy debate.

Both sides discussed metrics that appear in the record: respondents cited older studies of prepubertal children and higher rates of later desistance, while the challengers and amici pointed to district-court findings and more recent studies suggesting low rates of later regret among adolescents treated after the onset of puberty. During the argument, justices asked for precision: some cited figures like an 85 percent desistance statistic (from older prepubertal studies) and a much lower post-puberty regret figure discussed in the record (as low as about 1 percent in some analyses), and counsel debated the applicability of those numbers to the contested services.

Each side asked for different relief. Challenger counsel said a practical remedy would be an injunction preventing Tennessee from enforcing SB 1 as applied to the plaintiffs so they could continue previously prescribed care and asked the Court to vacate and remand for application of heightened scrutiny. The state urged affirmance of the Sixth Circuits rational-basis approach and emphasized that courts should not substitute judicial policy choices for legislative judgments.

At the end of the argument the Solicitor General offered brief rebuttal focusing on the district courts factual findings and on the harms that plaintiffs say they have already suffered. The case was submitted for decision.

The Court will now weigh doctrinal precedents about facial classifications, the evidentiary record assembled in the lower courts, and the scope of judicial review in matters that implicate contested medical science. The justices' questioning signaled no obvious consensus; the outcome will turn on how the Court characterizes SB 1s text and how it allocates the fact-intensive tailoring inquiry between itself and the lower courts.